AstraZeneca CEO Pascal Soriot (Getty Images)

Six days af­ter a star­tling tri­al halt, As­traZeneca gets a green light to re­sume dos­ing their Ox­ford Covid-19 vac­cine

Six days af­ter an abrupt and star­tling halt of their late-stage study of the Ox­ford vac­cine for Covid-19, As­traZeneca is back in busi­ness. And we al­so learned on Sat­ur­day that Pfiz­er and BioN­Tech are boost­ing the size of their fast-run­ning Phase III, with plans to add 14,000 peo­ple to the study to pro­vide a more di­verse group to test.

As­traZeneca put out a state­ment Sat­ur­day that UK reg­u­la­tors had of­fered a green light to start dos­ing again af­ter con­clud­ing that it was safe for vol­un­teers to take it. But the multi­na­tion­al play­er is not of­fer­ing any de­tailed in­for­ma­tion about the se­vere ad­verse event that stopped the study, trig­ger­ing head­lines around the globe.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA